三生国健(688336) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 119,356.83 million, an increase of 17.70% compared to the previous year[3] - Net profit attributable to the parent company reached RMB 73,165.99 million, reflecting a significant increase of 148.34% year-on-year[3] - The net profit after deducting non-recurring gains and losses was RMB 25,034.42 million, up by 21.16% from the previous year[3] - Basic earnings per share rose to RMB 1.19, representing a growth of 147.92% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 598,636.91 million, a 12.84% increase from the beginning of the year[4] - Equity attributable to the parent company increased to RMB 559,055.63 million, up 14.18% from the start of the year[4] Revenue Growth Drivers - The growth in operating revenue was primarily driven by a 17.74% increase in product sales revenue, with significant contributions from Yisaipu and CDMO business[7] Special Dividend Impact - The company received a special dividend of USD 6,242.47 million from its associate Numab Therapeutics, positively impacting its operating profit and net profit[7] Financial Position and Reporting - The company maintains a strong financial position with no uncertainties affecting the accuracy of the performance report[8] - Investors are advised to refer to the audited annual report for precise financial data and to be aware of investment risks[8]